New Long-Acting shot aims to tame acromegaly in phase 3 trial
NCT ID NCT07623824
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new long-acting octreotide injection (SYHX2008) in 154 adults with active acromegaly, a condition where the body makes too much growth hormone. The main goal is to see if the drug can bring hormone levels back to normal. Participants will receive the injection and be monitored for safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIAGNOSED WITH ACROMEGALY, CURRENTLY IN THE ACTIVE STAGE OF THE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.